What were the key takeaways from Lineage Cell's earnings call?

What is the market's earnings forecast for Lineage Cell next quarter?

What is the revenue and EPS growth rate for Lineage Cell year over year?

What were the key takeaways from Lineage Cell’s earnings call?

What is Lineage Cell's gross profit margin?

What is Lineage Cell's latest dividend and current dividend yield?

Did Lineage Cell beat or miss consensus estimates last quarter?

What guidance did Lineage Cell's management provide for the next earnings period?

- **OpRegen Momentum**: Genentech's 17-site expansion and 3-year visual improvement data highlight program strength, with potential Phase III readiness.
- **AlloSCOPE Breakthrough**: 0.5-liter islet cell production milestone solves industry scale challenge, positioning Lineage for commercial dominance.
- **Financial Resilience**: $55.8M cash runway extended to 2028, with $32M in exercisable warrants offering future liquidity.
- **Pipeline Expansion**: New cell type disclosure imminent, ReSonance hearing loss program advanced to preclinical stage in 1 year.

**【CEO Summary Section】**
- **OpRegen Progress**: CEO highlights confidence in OpRegen's potential for dry AMD, noting Genentech's expansion of clinical sites (17 total) and long-term data showing 3-year visual improvement. Roche's RMAT designation and device acquisition further validate program momentum.
- **AlloSCOPE Platform**: Demonstrates scalable manufacturing success with GMP-compliant pluripotent cell production, enabling millions of doses. Recent milestone: achieving 0.5-liter scale for islet cells, addressing a critical industry-wide scale challenge.
- **Islet Cell Initiative**: Met initial go/no-go milestone, focusing on undifferentiated cell scale-up before differentiation. Strategy prioritizes solving commercial-scale production over preclinical efficacy studies.
- **Pipeline Expansion**: New cell type program expected to be disclosed within 3-6 months. Hearing loss program (ReSonance) advanced to preclinical testing within 1 year, leveraging AlloSCOPE's efficiency.

**【CFO Financial Commentary】**
- **Financial Results**: Full-year 2025 net loss of $63.5M driven by non-cash warrant liability ($37.9M) and intangible asset impairment. Q4 revenue up 56% YoY to $6.6M due to Roche milestone and WDI collaboration.
- **Cash Runway**: $55.8M as of Q4, extended to Q2 2028 with $5.4M from March warrant exercises. Additional $32M in exercisable warrants priced below current share price, providing potential future liquidity.
- **Cost Management**: OpRegen R&D expenses down 28% YoY (excluding milestone-related accounting adjustments). Total R&D expenses up 45% YoY due to pipeline expansion.

**【Q&A Highlights】**
- **Islet Cell Scale-Up**: CEO emphasizes 0.5-liter milestone as proof-of-concept, with next step testing multi-liter scale. Cost containment strategy leverages existing GMP expertise and modular bioreactors.
- **OPC1 Trial Updates**: DOSED study enrolling chronic SCI patients; first participant shows no safety issues with new delivery device. FDA protocol amendment allows broader patient eligibility, accelerating enrollment.
- **OpRegen Phase III Readiness**: CEO notes manufacturing capacity sufficient for large trials but defers to Roche/Genentech on regulatory interactions. 3-year data durability supports long-term efficacy claims.
- **Warrant Exercise Impact**: CFO clarifies $5.4M from March exercises not included in current runway guidance, with remaining $32M in warrants offering future capital flexibility.

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

- **OpRegen Momentum**: 15 clinical sites opened, Genentech device acquisition, and independent competitor validation highlight potential for dry AMD treatment.
- **Pipeline Expansion**: $12M WDI collaboration for hearing loss, T1D islet cell therapy go/no-go Q1 2026, and CIRM grant ($7M potential) for spinal cord injury.
- **Financial Strength**: $40.5M cash runway to Q2 2027, with $37M warrant capital contingent on OpRegen trial announcement.
- **Strategic Flexibility**: Balance partnerships (e.g., WDI) with internal development, guided by manufacturing innovation and cost efficiency.

**【CEO Summary Section】**
- **OpRegen Progress**: Expanded clinical sites for GAlette study (15 total), with Genentech opening 8 new sites in 6 months. Positive signals include device acquisition for subretinal delivery and RMAT designation. Phase I/IIa data shows durable visual acuity improvements and safety. Competitor validation from multinational pharma reinforces potential.
- **Strategic Goals**: 
  1. **Partnerships**: $12M WDI collaboration for ReSonance hearing loss program, preserving future pharma deal rights.
  2. **Pipeline Expansion**: Early-stage work on multiple cell types; proprietary tracker identifies Type 1 Diabetes (T1D) islet cell therapy as top opportunity.
  3. **Manufacturing Innovation**: Scale-up efforts for T1D islet cells aim to overcome production limitations (1 billion cells/patient).
  4. **CIRM Grant**: $7M potential funding for OPC1 spinal cord injury study, with decision expected by Dec 11.
  5. **Milestone Revenue**: Progress on Roche/Genentech milestones, though specifics confidential.
- **Islet Cell Initiative**: Early-stage work suggests potential 1,000x production scale improvement. Go/no-go decision Q1 2026; could accelerate partnerships if successful.

**【CFO Financial Commentary】**
- **Cash Position**: $40.5M as of Q3, supporting operations into Q2 2027 (1 quarter longer than prior guidance). Includes $3.7M Q3 revenue (down 3% YoY) and $37M potential warrant capital if OpRegen enters controlled trial.
- **Expenses**: Operating expenses $7.5M (flat YoY). R&D $3.3M (+3%), G&A $4.2M (-5%). Net loss $29.8M driven by $26.6M warrant liability remeasurement.
- **Funding Sources**: WDI collaboration, CIRM grant, and Roche milestones. No OpRegen milestone revenue included in current cash runway.

**【Q&A Highlights】**
- **Islet Cell Program**: Go/no-go decision Q1 2026 hinges on feasibility of proprietary differentiation methods. Success could enable partnerships or internal advancement.
- **CIRM Grant**: $7M would offset 50% of OPC1 study costs. Reimbursement timeline delays cash impact but validates program value.
- **OpRegen Data**: Genentech likely to present GAlette findings at 2026 ophthalmology conferences. Device performance data shared with FDA for potential OPC1 formulation update.
- **Partnership Strategy**: Prioritize partners with disease expertise (e.g., WDI for hearing loss). Retain optionality to develop internally or partner based on capital efficiency.
- **OPC1 Dose Study**: First patient dosed July 30; no safety issues. FDA engagement on new cell formulation integration. Enrollment pace constrained by device learning curve and CIRM funding uncertainty.

Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript

- **OpRegen Breakthrough**: 20-letter visual acuity difference between treated and untreated eyes, with durability at 3 years. Lineage leads RPE transplant field with 4 independent companies reporting positive results.
- **OPC1 Milestone**: First chronic spinal cord injury patient treated using novel delivery device, enabling continuous ventilation. New manufacturing process aims for FDA clearance in 2025.
- **Financial Resilience**: $42.3M cash runway supports operations into 2027. Seeking $37M from Roche milestones and exploring nondilutive funding via partnerships and grants.
- **Strategic Expansion**: Leveraging cell therapy platform to enter new therapeutic areas, with preclinical hearing loss program advancing.

**【CEO Summary Section】**
- **OpRegen Program Update**: Phase I/IIa trial shows 9-letter vision gain in treated eyes vs. 11-letter loss in untreated eyes, with effects lasting 3 years. 4 companies now report positive RPE transplant outcomes, validating Lineage's leadership. Partnership with Roche/Genentech provides clinical and commercial expertise.
- **OPC1 Spinal Cord Program**: First chronic patient treated in DOSED study using new delivery device, eliminating the need to stop ventilation. New manufacturing process improves purity and scale, with FDA clearance pending for open enrollment.
- **Strategic Initiatives**: Expanding into new therapeutic areas (e.g., hearing loss) using directed differentiation platform. Seeking nondilutive funding through partnerships, grants (e.g., CIRM), and Roche milestones ($37M potential).

**【CFO Financial Commentary】**
- **Cash Position**: $42.3M as of Q2 2025, supporting operations into Q1 2027.
- **Revenue**: $2.8M (vs. $1.4M in Q2 2024), driven by Roche collaboration and deferred revenue recognition.
- **Expenses**: $22.5M (vs. $7.3M in Q2 2024), including $14.8M impairment loss on VAC platform.
- **Net Loss**: $30.5M ($0.13/share), primarily due to warrant liability remeasurement ($12.7M).

**【Q&A Highlights】**
- **DOSED Study Enrollment**: Initial staggered approach with 4 patients; FDA safety monitoring board reviews after 30 days. Chronic patients may enroll faster due to existing care, while subacute patients require timely intervention.
- **Manufacturing Progress**: New immediate-use OPC1 formulation eliminates preparation steps. GMP banking platform capable of millions of doses for OpRegen.
- **Partnership Strategy**: Actively pursuing collaborations for new programs (e.g., hearing loss) and leveraging platform capabilities to attract funding.

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2025 Earnings Call Transcript

- **OpRegen Clinical Momentum**: 36-month data presentation in June 2025; independent RPE trials validate functional benefits, reinforcing OpRegen's potential as a one-time treatment vs. monthly anti-complement therapy.
- **Manufacturing Breakthrough**: First-in-field GMP production of millions of doses from single cell line, sparking early partnership discussions.
- **OPC1 Trial Advancement**: New delivery device to avoid ventilation cessation; immediate-use formulation reduces handling complexity; planning for larger trial post-device validation.
- **Financial Stability**: $47.9M cash runway; $1.5M Q1 revenue driven by Roche collaboration; net loss narrowed to $4.1M YoY.
- **Strategic Expansion**: Leveraging manufacturing expertise to explore collaborations, positioning for non-dilutive growth.


**【CEO Summary Section】**
- **OpRegen Program Update**: Phase 2a GAlette Study progressing with Genentech, with 36-month clinical data to be presented at CTS 2025. Independent RPE cell transplant trials (e.g., two competitors at ARVO 2025) validate functional benefits of one-time dosing, aligning with OpRegen's vision. Genentech's RMAT designation and proprietary surgical devices signal commitment to optimization.
- **Manufacturing Milestone**: Achieved GMP production of millions of doses from a single pluripotent cell line, enabling low-cost, scalable supply for large patient populations. This capability has sparked early-stage partnership discussions.
- **OPC1 Spinal Cord Injury Trial**: Dose study (DOSED) to evaluate new delivery device in 6-10 patients, aiming to avoid ventilation cessation during cell administration. Immediate-use thaw-and-inject formulation reduces handling complexity. Planning for larger trial with refined endpoints post-device validation.
- **Strategic Expansion**: Leveraging manufacturing expertise to explore collaborations beyond OpRegen, positioning for non-dilutive growth opportunities.

**【CFO Financial Commentary】**
- **Cash Position**: $47.9M as of Q1 2025, supporting operations into Q1 2027. $37M warrant capital potentially available.
- **Revenue**: $1.5M (Q1 2025) vs. $1.4M (Q1 2024), driven by Roche collaboration revenue.
- **Expenses**: Operating expenses $8.0M (flat vs. Q1 2024). R&D $3.1M (+$0.1M), G&A $4.9M (stable). Net loss $4.1M (-$2.4M YoY) due to warrant liability fair value changes.

**【Q&A Highlights】**
- **Manufacturing Differentiation**: Lineage's GMP dual banking system enables exponential scale (e.g., 1M+ doses from single cell line), unlike peers' unvalidated claims. No plans to become a CDMO; focus on strategic partnerships.
- **Tariff Mitigation**: Israeli manufacturing site unaffected by tariffs; materials pre-purchased to avoid supply chain risks.
- **OPC1 Trial Design**: Single-arm, open-label study with staggered enrollment (first 3 patients: thoracic injuries; subsequent: cervical). Primary safety endpoint at 30 days; functional assessments at 6-12 months.
- **FDA Regulatory Outlook**: CEO optimistic about CBER director's focus on data-driven innovation, aligning with OpRegen's clinical magnitude of benefit.


Lineage Cell Therapeutics, Inc. (LCTX) Q1 2025 Earnings Call Transcript

- **OpRegen Clinical Excellence**: 3-year data shows durable vision gains, outperforming degenerative trends. Competitor RPE programs validate modality, with Genentech pursuing controlled trials.
- **Manufacturing Leadership**: Achieved 1 million-dose production scale, enabling commercial viability for large markets. Patented process provides strategic advantage over peers.
- **OPC1 Innovation**: DOSED study deploys novel delivery device, reducing procedure complexity. Immediate-use cell formulation streamlines clinical workflow.
- **Financial Resilience**: $47.8M cash runway to 2027, with $36M contingent funding for OpRegen success. Narrowed net loss 13% YoY, reflecting cost efficiency.


**【CEO Key Updates】**
- **OpRegen Progress**: 3-year data shows sustained vision gains (BCVA above baseline) in 5 patients, contrasting with degenerative trends in comparator therapies. Competitor RPE programs report positive 12-month results, supporting the modality's potential. Genentech obtained RMAT designation and expanded manufacturing collaboration with Lineage.
- **Manufacturing Scale**: Achieved scalable GMP production capable of 1 million doses, leveraging OpRegen's process for future programs. New cell bank validation (100 vials → 1 million doses) positions Lineage for commercial success in large markets.
- **OPC1 Advancements**: DOSED study begins Q2 with novel delivery device (4-5 min administration without stopping ventilation). Improved manufacturing process eliminates pre-dose preparation, enhancing clinical efficiency. CIRM grant application planned for spring 2025.

**【CFO Financial Highlights】**
- **Cash Position**: $47.8M as of Q4 2024, extended runway to Q1 2027 post-$5.5M direct offering. Milestone warrant offers $36M contingent on OpRegen clinical success.
- **Revenue & Expenses**: Q4 2024 revenue $2.9M (vs. $2.1M 2023), driven by Roche collaboration. Operating expenses $7.8M (down 5% YoY). Full-year net loss $18.6M, narrowed 13% YoY.
- **Financial Strategy**: Balancing cost control with strategic investments, exploring grants and partnerships for capital diversification.

**【Q&A Key Takeaways】**
- **OpRegen Timing**: Genentech may initiate controlled trials without completing GAlette, accelerating warrant maturity. 3-year data presentation depends on Genentech's conference selection.
- **OPC1 Logistics**: DOSED study prioritizes thoracic AIS-A patients for safety, expanding to cervical injuries post-initial phase. FDA approval for new cell formulation contingent on comparability studies.
- **Market Competition**: Lineage's manufacturing scale (million-dose capability) and Genentech/Roche partnership differentiate OpRegen from competitors with unproven scalability.


Actual											-0.06	-0.04	-0.05	0.01	-0.01	-0.03	-0.05	-0.17	-0.04	-0.04	-0.04	-0.03	-0.03	-0.03	-0.04	-0.03	-0.04	-0.03	-0.02	-0.02	-0.02	-0.13	-0.13	0.02
Forecast											-0.035	-0.04	-0.0467	-0.042	-0.04	-0.035	-0.048	-0.0517	-0.022	-0.0329	-0.035	-0.04	-0.038	-0.0443	-0.0417	-0.0429	-0.0383	-0.045	-0.04	-0.03	-0.0257	-0.0267	-0.0257	-0.0429
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-71.43%	0.00%	-7.07%	+123.81%	+75.00%	+14.29%	-4.17%	-228.82%	-81.82%	-21.58%	-14.29%	+25.00%	+21.05%	+32.28%	+4.08%	+30.07%	-4.44%	+33.33%	+50.00%	+33.33%	+22.18%	-386.89%	-405.84%	+146.62%

LCTX

LCTX fundamentals

LCTX Q4 2025 Earnings

Earnings Call

You can ask Aime

LCTX

LCTX fundamentals

LCTX Q4 2025 Earnings

Earnings Call

LCTX Earnings Call Summary for Q4/20254:30 PM on Mar 5, 2026

LCTX Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

LCTX Earnings Call Summary for Q2/20254:30 PM on Aug 12, 2025

LCTX Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

LCTX Earnings Call Summary for Q4/20244:30 PM on Mar 10, 2025

You can ask Aime